BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36218255)

  • 1. [Guillain-Barre syndrome and thrombocytopenia after SARS-CoV-2 vaccination with Moderna. A case report].
    Lázaro C; Llauradó A; Sánchez-Tejerina D; Cabirta A; Carpio C; Sotoca J; Salvadó M; Raguer N; Restrepo J; Juntas R
    Rev Neurol; 2022 Oct; 75(8):247-250. PubMed ID: 36218255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports.
    Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA
    Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine.
    Algahtani HA; Shirah BH; Albeladi YK; Albeladi RK
    Acta Neurol Taiwan; 2023 Jun; 32(2)():82-85. PubMed ID: 37198513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Report of Guillain-Barré Syndrome In Association with SARS-CoV-2 Vaccination in Malaysia.
    Sii HL; Ng SH; Wong VF; Law WC
    Acta Neurol Taiwan; 2023 Dec; 32(4)():207-211. PubMed ID: 37723913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
    Introna A; Caputo F; Santoro C; Guerra T; Ucci M; Mezzapesa DM; Trojano M
    Clin Neurol Neurosurg; 2021 Sep; 208():106887. PubMed ID: 34418708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
    Jacobs JW; Booth GS; Adkins BD
    Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guillain-Barré Syndrome Associated with COVID-19 Vaccination.
    Finsterer J; Scorza FA; Scorza CA
    Emerg Infect Dis; 2022 May; 28(5):1079-1080. PubMed ID: 35447058
    [No Abstract]   [Full Text] [Related]  

  • 10. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.
    Allen CM; Ramsamy S; Tarr AW; Tighe PJ; Irving WL; Tanasescu R; Evans JR
    Ann Neurol; 2021 Aug; 90(2):315-318. PubMed ID: 34114269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN.
    Tutar NK; Eyigürbüz T; Yildirim Z; Kale N
    Ideggyogy Sz; 2021 Jul; 74(7-08):286-288. PubMed ID: 34370408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Are the Risks of Guillain-Barré Syndrome After SARS-CoV-2 Infection and COVID-19 Vaccination?
    Bourdette D; Silbermann E
    Neurology; 2023 Nov; 101(20):875-876. PubMed ID: 37852787
    [No Abstract]   [Full Text] [Related]  

  • 13. Guillain-Barré syndrome after COVID-19 vaccination.
    McKean N; Chircop C
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34330729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report.
    Masuccio FG; Comi C; Solaro C
    Acta Neurol Belg; 2022 Oct; 122(5):1369-1371. PubMed ID: 34767184
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors.
    Rzymski P
    Front Immunol; 2023; 14():1183258. PubMed ID: 37180147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
    Lahoz Fernandez PE; Miranda Pereira J; Fonseca Risso I; Baleeiro Rodrigues Silva P; Freitas Barboza IC; Vieira Silveira CG; Diogo Silva G; Marzorati Kuntz Puglia P; Genaro Mutarelli E
    Acta Neurol Scand; 2022 Apr; 145(4):393-398. PubMed ID: 34967005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barre syndrome related to SARS-CoV-2 vaccinations.
    Finsterer J; Scorza CA; Scorza FA
    Clinics (Sao Paulo); 2022; 77():100113. PubMed ID: 36137343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.